Redirecting Poor Sleep Drivers of Early Cardiovascular Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-70
SponsorNational University of Singapore

About this trial

Sleep health is a critical component of cardiovascular well-being, and poor sleep has been linked with increased risk for all-cause mortality including cardiovascular disease (CVD). Moreover, many individuals within a population may have underlying, subclinical cardiovascular conditions, such as hypertension and arterial stiffness, and these may risk progressing to advanced CVD when coupled with inadequate sleep duration and quality. Given that Singapore ranks as the third most sleep-deprived city globally, understanding the relationship between sleep health and the prevalence and progression of CVD becomes increasingly important for population health. In addition, depression and psychological stress could also lead to poorer cardiovascular health by increasing blood cholesterol, blood sugar and blood pressure, and could also be directly related to or arise as a result of poor sleep. The aim of the current study is to track sleep and mental health using a combination of objective sleep tracking (Oura ring) and smartphone-based questionnaires (EMA), and examine their associations with detailed cardiovascular health data collected by the project RESET (Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease).

Eligibility criteria

Qualifiers

Willing to wear a ring

High blood pressure

High cholesterol

Fatty liver

Disqualifiers

Prior history of heart attack or stroke or balloon angioplasty/stent placement

Restricted peripheral circulation (e.g., Raynaud's disease)

Pacemakers

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,500 Participants
are grouped into 1 trial group